Interim Guidance: Preexposure Prophylaxis for the Prevention of HIV Infection in Men Who Have Sex with Men

An estimated 56,000 human immunodeficiency virus (HIV) infections occur each year in the United States. Men who have sex with men (MSM) account for 53% of the estimated incident infections, and surveillance data suggest that the annual number of new HIV infections among MSM has been rising since the...

Full description

Saved in:

Bibliographic Details
Published in:	MMWR. Morbidity and mortality weekly report Vol. 60; no. 3; pp. 65 - 68
Main Authors:	Smith, D.K, Grant, R.M, Weidle, P.J, Lansky, A, Mermin, J, Fenton, K.A
Format:	Journal Article Newsletter
Language:	English
Published:	United States Centers for Disease Control and Prevention 28-01-2011 U.S. Government Printing Office U.S. Center for Disease Control
Subjects:	Adenine - administration & dosage Adenine - analogs & derivatives Antiviral Agents - therapeutic use Clinical trials Condoms Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Disease prevention Disease transmission Double-Blind Method Drug Therapy, Combination Emtricitabine Experimentation Gays & lesbians Hepatitis B HIV HIV (Viruses) HIV infection HIV infections HIV Infections - prevention & control HIV testing Homosexuality, Male Human immunodeficiency virus Humans Infections Male Medical research Medication adherence Medications Medicine, Experimental Organophosphonates - administration & dosage Pills Prevention Sexually transmitted diseases Tenofovir Unsafe Sex
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	An estimated 56,000 human immunodeficiency virus (HIV) infections occur each year in the United States. Men who have sex with men (MSM) account for 53% of the estimated incident infections, and surveillance data suggest that the annual number of new HIV infections among MSM has been rising since the mid-1990s. Strategies for reducing acquisition of HIV infection by MSM have included 1) expanded HIV testing so that infected persons can be treated and their risk for transmitting infection minimized; 2) individual, small-group, and community-level behavioral interventions to reduce risk behaviors; 3) promotion of condom use; 4) detection and treatment of sexually transmitted infections; and 5) mental health and substance abuse counseling when needed. On November 23, 2010, investigators for the Pre-Exposure Prophylaxis Initiative (iPrEX) study announced results from a multinational, randomized, double-blind, placebo-controlled, phase III clinical trial of daily oral antiretrovirals (tenofovir disoproxil fumarate [TDF] and emtricitabine [FTC]) to prevent acquisition of HIV infection among uninfected but exposed MSM. This report provides interim guidance to health-care providers based on the reported results of that trial, which indicated that TDF plus FTC taken orally once a day as preexposure prophylaxis (PrEP) is safe and partially effective in reducing HIV acquisition among MSM when provided with regular monitoring of HIV status and ongoing risk-reduction and PrEP medication adherence counseling.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-News-2 ObjectType-Feature-3 content type line 23
ISSN:	0149-2195 1545-861X